Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Purchased by Pictet Asset Management SA

Pictet Asset Management SA raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGNGet Rating) by 6.5% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 173,410 shares of the company’s stock after purchasing an additional 10,615 shares during the quarter. Pictet Asset Management SA’s holdings in Myriad Genetics were worth $3,151,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of MYGN. Mutual of America Capital Management LLC lifted its holdings in shares of Myriad Genetics by 5.5% during the 1st quarter. Mutual of America Capital Management LLC now owns 11,507 shares of the company’s stock valued at $290,000 after acquiring an additional 597 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Myriad Genetics by 2.8% during the 1st quarter. Arizona State Retirement System now owns 21,586 shares of the company’s stock valued at $544,000 after buying an additional 578 shares during the period. Envestnet Asset Management Inc. lifted its position in Myriad Genetics by 6.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 139,540 shares of the company’s stock worth $3,516,000 after acquiring an additional 8,670 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Myriad Genetics by 24.4% in the 1st quarter. Victory Capital Management Inc. now owns 49,378 shares of the company’s stock worth $1,012,000 after acquiring an additional 9,691 shares during the period. Finally, Advisor Group Holdings Inc. grew its position in Myriad Genetics by 13.3% in the first quarter. Advisor Group Holdings Inc. now owns 19,365 shares of the company’s stock valued at $488,000 after acquiring an additional 2,272 shares in the last quarter. Institutional investors and hedge funds own 99.80% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on MYGN shares. StockNews.com started coverage on shares of Myriad Genetics in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Stephens started coverage on shares of Myriad Genetics in a research report on Wednesday, October 5th. They issued an “equal weight” rating and a $22.00 price objective for the company. Cowen increased their price objective on shares of Myriad Genetics to $32.00 in a research report on Tuesday, August 9th. Finally, SVB Leerink lowered their price objective on shares of Myriad Genetics from $27.00 to $25.00 and set a “market perform” rating for the company in a research report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating and three have given a hold rating to the company’s stock. According to MarketBeat.com, Myriad Genetics currently has an average rating of “Hold” and a consensus price target of $25.50.

Myriad Genetics Trading Down 1.3 %

Myriad Genetics stock opened at $19.02 on Monday. The stock has a market cap of $1.54 billion, a P/E ratio of -19.61 and a beta of 1.71. The stock has a 50 day moving average of $19.55 and a 200-day moving average of $21.01. Myriad Genetics, Inc. has a 52 week low of $15.38 and a 52 week high of $28.60.

About Myriad Genetics

(Get Rating)

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Featured Articles

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGNGet Rating).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.